IP Library Granted Patent US 8,378,081
Granted Patent B2
US 8,378,081 · App. 12/533,348 · Granted Feb 19, 2013

Antibodies that specifically bind to Aβ oligomers and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,378,081
App. No.
12/533,348
Granted
Feb 19, 2013
Kind
B2
Abstract

The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.

Claims (7)

1. An isolated antibody that binds to an Aβ oligomer and which comprises an H chain having the amino acid sequence of SEQ ID NO: 81, an L chain having the amino acid sequence of SEQ ID NO: 83, or both.

2. An isolated antibody that binds to an Aβ oligomer, and which is selected from the group consisting of:

(1) an antibody that comprises (i) an H chain having the amino acid sequence of SEQ ID NO: 89 as CDR1, the amino acid sequence of SEQ ID NO: 91 as CDR2, and the amino acid sequence of SEQ ID NO: 93 as CDR3; and (ii) an L chain having the amino acid sequence of SEQ ID NO: 95 as CDR1, the amino acid sequence of SEQ ID NO: 97 as CDR2, and the amino acid sequence of SEQ ID NO: 99 as CDR3;

(2) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 85 as VH; and

(3) an antibody that comprises (i) an H chain having the amino acid sequence of SEQ ID NO: 85 as VH and (ii) an L chain having the amino acid sequence of SEQ ID NO: 87 as VL.

3. The antibody of claim 2 , wherein the antibody is a chimeric antibody or a humanized antibody.

4. A composition comprising the antibody of claim 1 or 2 and a pharmaceutically acceptable carrier.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2024
From: IMMUNAS PHARMA, INC.
To: ONCOTHERAPY SCIENCE, INC.
Reel/Frame 069276/0718 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NUMERIC PART OF THE ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED ON REEL 025968 FRAME 0001. ASSIGNOR(S) HEREBY CONFIRMS THE 35, GENGO, MORIOKA-MACHI, OBU-SHI, AICHI, JAPAN 4748511. Recorded May 5, 2011
From: JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY
To: NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY
Reel/Frame 026226/0178 →
CHANGE OF NAME Recorded Mar 16, 2011
From: JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY
To: NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY
Reel/Frame 025968/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2009
From: MATSUBARA, ETSURO
To: JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY
Reel/Frame 023393/0364 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2009
From: SHIBATA, MASAO; YOKOSEKI, TATSUKI
To: IMMUNAS PHARMA, INC.
Reel/Frame 023391/0836 →